<p>Bright Minds Biosciences Inc. (NASDAQ:DRUG - 获取免费报告) 在一月份的空头头寸大幅增长。截至 1 月 15 日，空头头寸总计为 564,277 股，比 12 月 31 日的 336,924 股增长了 67.5%。根据平均每日交易量 362,208 股，目前的覆盖天数比率为 1.6 天。目前，该股票的 10.1% 股份被做空。目前，该股票的 10.1% 股份被做空。根据平均每日交易量 362,208 股，目前的覆盖天数比率为 1.6 天。</p>
<h2>华尔街分析师预测增长</h2>
<ul>
<li>生物科技行业的边缘：2 只具有巨大潜力的股票</li>
</ul>
<p>几位研究分析师最近对 DRUG 股票发布了报告。Cantor Fitzgerald 在 12 月 1 日的报告中重申了对 Bright Minds Biosciences 股票的 “增持” 评级。Zacks Research 在 12 月 2 日的研究报告中将 Bright Minds Biosciences 的评级从 “强烈买入” 下调至 “持有”。Chardan Capital 在 1 月 2 日的研究报告中重申了 “买入” 评级，并设定了 Bright Minds Biosciences 股票的目标价为 80.00 美元。HC Wainwright 在 12 月 30 日的报告中重申了 “买入” 评级，并对 Bright Minds Biosciences 股票的目标价为 115.00 美元。最后，Robert W. Baird 在 1 月 7 日的研究报告中设定了 Bright Minds Biosciences 的目标价为 142.00 美元。五位分析师对该股票给予了买入评级，一位分析师给予了持有评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “适度买入”，平均目标价为 121.00 美元。</p>
<p><strong>查看我们关于 DRUG 的最新报告</strong></p>
<h2>Bright Minds Biosciences 价格表现</h2>
<ul>
<li>Bright Minds Biosciences 股票暴涨近 1500%</li>
</ul>
<p>NASDAQ:DRUG 的股票在周五下跌 4.73 美元，达到 77.75 美元。该公司交易了 197,018 股，较其平均交易量 240,786 股有所减少。该股票的市值为 7.5651 亿美元，市盈率为-63.73，贝塔值为-6.15。该公司的 50 日移动平均线为 81.91 美元，200 日移动平均线为 59.82 美元。Bright Minds Biosciences 的 52 周低点为 23.17 美元，52 周高点为 123.75 美元。</p>
<h2>对 Bright Minds Biosciences 的对冲基金看法</h2>
<p>机构投资者最近买入和卖出了该股票的股份。新泽西州警察和消防员退休系统在第二季度购买了 Bright Minds Biosciences 的新股份，价值约 28,000 美元。摩根大通在第二季度将其在 Bright Minds Biosciences 的持股增加了 624.3%。摩根大通现在拥有 2,173 股该公司的股票，价值 57,000 美元，此前在该期间内又购买了 1,873 股。拉塞尔投资集团在第三季度购买了 Bright Minds Biosciences 的新股份，价值约 58,000 美元。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第二季度购买了 Bright Minds Biosciences 的新股份，价值约 66,000 美元。最后，Gordian Capital Singapore Pte Ltd 在第三季度获得了 Bright Minds Biosciences 的新头寸，价值约 73,000 美元。对冲基金和其他机构投资者持有该公司 40.52% 的股份。</p>
<h2>Bright Minds Biosciences 公司简介</h2>
<p>(获取免费报告)</p>
<p>Bright Minds Biosciences Inc.在纳斯达克以 DRUG 为交易代码，是一家临床阶段的生物技术公司，专注于开发用于心理健康和神经退行性疾病的新型小分子治疗药物。该公司的研究利用专有化学平台创造源自迷幻药结构的调节血清素和神经保护化合物。Bright Minds 旨在通过口服治疗解决重度抑郁症、创伤后应激障碍和阿尔茨海默病等未满足的需求。</p>
<p>该公司的主要候选药物 BMB-101 是一种口服 5-HT2A 受体调节化合物，正在临床开发中，针对情绪和焦虑障碍。</p>
<h2>进一步阅读</h2>
<ul>
<li>五只我们更看好的股票，胜过 Bright Minds Biosciences</li>
<li>请勿删除，请立即阅读</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>用这 4 个简单步骤 “防止美联储影响” 你的银行账户</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>崩盘已经开始（大多数人只是还没看到）</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Bright Minds Biosciences 吗？</h2>
<p>在你考虑 Bright Minds Biosciences 之前，你会想听听这个。</p>
<p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 Bright Minds Biosciences 并不在名单上。</p>
<p>虽然 Bright Minds Biosciences 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

医疗业 ETF - SPDR

动态生物技术与基因组 ETF - Invesco

标普生物技术 ETF - SPDR

<p>Bright Minds Biosciences Inc.（纳斯达克代码：DRUG）在短期空头头寸方面经历了显著增长，1 月份上涨了 67.5%，总计达到 564,277 股。目前，该公司 10.1% 的股份被做空，基于平均每日交易量 362,208 股，覆盖天数比率为 1.6 天。分析师对该股票的评级意见不一，普遍评级为 “适度买入”，平均目标价格为 121.00 美元。该股票近期波动较大，最近交易价格为 77.75 美元，下跌了 4.73 美元</p>

<p>Bright Minds Biosciences Inc. (NASDAQ:DRUG - Get Free Report) saw a large growth in short interest in January. As of January 15th, there was short interest totaling 564,277 shares, a growth of 67.5% from the December 31st total of 336,924 shares. Based on an average daily trading volume, of 362,208 shares, the days-to-cover ratio is currently 1.6 days. Currently, 10.1% of the shares of the stock are short sold. Currently, 10.1% of the shares of the stock are short sold. Based on an average daily trading volume, of 362,208 shares, the days-to-cover ratio is currently 1.6 days.</p>
<div class="lb-trans"><p>Bright Minds Biosciences Inc. (NASDAQ:DRUG - 获取免费报告) 在一月份的空头头寸大幅增长。截至 1 月 15 日，空头头寸总计为 564,277 股，比 12 月 31 日的 336,924 股增长了 67.5%。根据平均每日交易量 362,208 股，目前的覆盖天数比率为 1.6 天。目前，该股票的 10.1% 股份被做空。目前，该股票的 10.1% 股份被做空。根据平均每日交易量 362,208 股，目前的覆盖天数比率为 1.6 天。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><ul>
<li>Biotechs on the Brink: 2 Stocks With Huge Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>生物科技行业的边缘：2 只具有巨大潜力的股票</li>
</ul>
</div><p>Several research analysts have recently issued reports on DRUG shares. Cantor Fitzgerald reiterated an &#34;overweight&#34; rating on shares of Bright Minds Biosciences in a report on Monday, December 1st. Zacks Research lowered Bright Minds Biosciences from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Tuesday, December 2nd. Chardan Capital reiterated a &#34;buy&#34; rating and set a $80.00 price target on shares of Bright Minds Biosciences in a research report on Friday, January 2nd. HC Wainwright restated a &#34;buy&#34; rating and issued a $115.00 price objective on shares of Bright Minds Biosciences in a report on Tuesday, December 30th. Finally, Robert W. Baird set a $142.00 target price on Bright Minds Biosciences in a research note on Wednesday, January 7th. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $121.00.</p>
<div class="lb-trans"><p>几位研究分析师最近对 DRUG 股票发布了报告。Cantor Fitzgerald 在 12 月 1 日的报告中重申了对 Bright Minds Biosciences 股票的 “增持” 评级。Zacks Research 在 12 月 2 日的研究报告中将 Bright Minds Biosciences 的评级从 “强烈买入” 下调至 “持有”。Chardan Capital 在 1 月 2 日的研究报告中重申了 “买入” 评级，并设定了 Bright Minds Biosciences 股票的目标价为 80.00 美元。HC Wainwright 在 12 月 30 日的报告中重申了 “买入” 评级，并对 Bright Minds Biosciences 股票的目标价为 115.00 美元。最后，Robert W. Baird 在 1 月 7 日的研究报告中设定了 Bright Minds Biosciences 的目标价为 142.00 美元。五位分析师对该股票给予了买入评级，一位分析师给予了持有评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “适度买入”，平均目标价为 121.00 美元。</p>
</div><p><strong>View Our Latest Report on DRUG</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 DRUG 的最新报告</strong></p>
</div><h2>Bright Minds Biosciences Price Performance</h2>
<div class="lb-trans"><h2>Bright Minds Biosciences 价格表现</h2>
</div><ul>
<li>Bright Minds Biosciences Stock Surges Almost 1,500%</li>
</ul>
<div class="lb-trans"><ul>
<li>Bright Minds Biosciences 股票暴涨近 1500%</li>
</ul>
</div><p>Shares of NASDAQ:DRUG traded down $4.73 on Friday, reaching $77.75. 197,018 shares of the company traded hands, compared to its average volume of 240,786. The stock has a market capitalization of $756.51 million, a PE ratio of -63.73 and a beta of -6.15. The company's 50 day moving average is $81.91 and its 200-day moving average is $59.82. Bright Minds Biosciences has a fifty-two week low of $23.17 and a fifty-two week high of $123.75.</p>
<div class="lb-trans"><p>NASDAQ:DRUG 的股票在周五下跌 4.73 美元，达到 77.75 美元。该公司交易了 197,018 股，较其平均交易量 240,786 股有所减少。该股票的市值为 7.5651 亿美元，市盈率为-63.73，贝塔值为-6.15。该公司的 50 日移动平均线为 81.91 美元，200 日移动平均线为 59.82 美元。Bright Minds Biosciences 的 52 周低点为 23.17 美元，52 周高点为 123.75 美元。</p>
</div><h2>Hedge Funds Weigh In On Bright Minds Biosciences</h2>
<div class="lb-trans"><h2>对 Bright Minds Biosciences 的对冲基金看法</h2>
</div><p>Institutional investors have recently bought and sold shares of the stock. Police &amp; Firemen s Retirement System of New Jersey purchased a new stake in Bright Minds Biosciences during the second quarter valued at about $28,000. JPMorgan Chase &amp; Co. raised its holdings in shares of Bright Minds Biosciences by 624.3% during the second quarter. JPMorgan Chase &amp; Co. now owns 2,173 shares of the company's stock valued at $57,000 after acquiring an additional 1,873 shares during the period. Russell Investments Group Ltd. purchased a new stake in shares of Bright Minds Biosciences in the 3rd quarter valued at approximately $58,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Bright Minds Biosciences in the 2nd quarter valued at approximately $66,000. Finally, Gordian Capital Singapore Pte Ltd acquired a new position in Bright Minds Biosciences in the 3rd quarter worth approximately $73,000. Hedge funds and other institutional investors own 40.52% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者最近买入和卖出了该股票的股份。新泽西州警察和消防员退休系统在第二季度购买了 Bright Minds Biosciences 的新股份，价值约 28,000 美元。摩根大通在第二季度将其在 Bright Minds Biosciences 的持股增加了 624.3%。摩根大通现在拥有 2,173 股该公司的股票，价值 57,000 美元，此前在该期间内又购买了 1,873 股。拉塞尔投资集团在第三季度购买了 Bright Minds Biosciences 的新股份，价值约 58,000 美元。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第二季度购买了 Bright Minds Biosciences 的新股份，价值约 66,000 美元。最后，Gordian Capital Singapore Pte Ltd 在第三季度获得了 Bright Minds Biosciences 的新头寸，价值约 73,000 美元。对冲基金和其他机构投资者持有该公司 40.52% 的股份。</p>
</div><h2>Bright Minds Biosciences Company Profile</h2>
<div class="lb-trans"><h2>Bright Minds Biosciences 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Bright Minds Biosciences Inc, trading on the NASDAQ under the symbol DRUG, is a clinical-stage biotechnology company focused on developing novel small-molecule therapeutics for mental health and neurodegenerative disorders. The company’s research leverages proprietary chemistry platforms to create serotonin-modulating and neuroprotective compounds derived from psychedelic-inspired structures. Bright Minds aims to address unmet needs in conditions such as major depressive disorder, post-traumatic stress disorder and Alzheimer’s disease through orally administered treatments.</p>
<div class="lb-trans"><p>Bright Minds Biosciences Inc.在纳斯达克以 DRUG 为交易代码，是一家临床阶段的生物技术公司，专注于开发用于心理健康和神经退行性疾病的新型小分子治疗药物。该公司的研究利用专有化学平台创造源自迷幻药结构的调节血清素和神经保护化合物。Bright Minds 旨在通过口服治疗解决重度抑郁症、创伤后应激障碍和阿尔茨海默病等未满足的需求。</p>
</div><p>The company’s lead candidate, BMB-101, is an oral 5-HT2A receptor-modulating compound in clinical development for mood and anxiety disorders.</p>
<div class="lb-trans"><p>该公司的主要候选药物 BMB-101 是一种口服 5-HT2A 受体调节化合物，正在临床开发中，针对情绪和焦虑障碍。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Bright Minds Biosciences</li>
<li>Do not delete, read immediately</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
<li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li>
<li>A U.S. “birthright” claim worth trillions - activated quietly</li>
<li>The Crash Has Already Started (Most Just Don’t See It Yet)</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Bright Minds Biosciences</li>
<li>请勿删除，请立即阅读</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>用这 4 个简单步骤 “防止美联储影响” 你的银行账户</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>崩盘已经开始（大多数人只是还没看到）</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Bright Minds Biosciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Bright Minds Biosciences 吗？</h2>
</div><p>Before you consider Bright Minds Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Bright Minds Biosciences 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bright Minds Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 Bright Minds Biosciences 并不在名单上。</p>
</div><p>While Bright Minds Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Bright Minds Biosciences 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Short Interest in Bright Minds Biosciences Inc. (NASDAQ:DRUG) Rises By 67.5%

Market Beat

纽交所高增长板生物技术指数 ETF - First Trust

美国制药 ETF - iShares

2 倍做多纳斯达克生物技术 ETF - ProShares

纳斯达克生物科技指数 ETF - iShares Nasdaq

基因改革 ETF - ARK

生物科技 ETF - VanEck Vectors

医药突破 ETF - ALPS

标普全球医疗股指数 ETF - iShares

Bright Minds Biosciences

医疗业 ETF - Vanguard

Bright Minds Biosciences Inc.（纳斯达克股票代码：DRUG）的空头头寸增加了 67.5%